Background
Bladder cancer (BC) is the most common urologic cancer. Approximately 429,800 newly diagnosed cases and 165,100 deaths are recorded worldwide every year [
1]. The main pathological bladder cancer types are bladder urothelial carcinoma (BUC), bladder adenocarcinoma and bladder squamous cell carcinoma. The most common type is BUC and accounts for more than 90% of all BCs [
2]. Unfortunately, the high recurrence rate is a characteristic of BUC [
3,
4]. Currently, the principal treatment strategy for BUC consists of surgery and adjuvant combination chemotherapy. However, chemotherapy resistance reduces the sensitivity of BUC to chemotherapeutic drugs and frequently results in treatment failure resulting in BUC clinical management being a major challenge [
5]. In addition, only a limited number of biomarkers are available for diagnosing BUC compared to other cancers. Hence, identifying sensitive and specific BUC biomarkers, as well as therapeutic targets for BUC are critically needed.
Long non-coding RNAs (lncRNAs) are a subtype of ncRNAs with transcript lengths over 200 nucleotides and have recently attracted increased attention [
6]. lncRNAs were initially regarded as transcriptional noise without the capacity to encode proteins [
7]. However, growing evidence has demonstrated that lncRNAs may play crucial biological roles in a variety of biological processes that are associated with carcinogenesis and cancer metastasis [
8]. With regards to bladder cancer, several studies have suggested that lncRNAs may function as oncogenes or tumor suppressors and may affect overall patient survival and mortality [
9,
10]. To date, only a few lncRNAs have been verified experimentally, but their roles in regulating gene expression remains to be deciphered.
Considerable efforts have been made to demonstrate how lncRNAs exert their diverse biological functions in human malignant tumors. Rapid progression has been made to elucidate the role of lncRNAs in miRNA function. miRNAs are endogenous single-stranded RNA with lengths between 20 and 25 nucleotides that do not encode proteins. They repress gene expression by complement binding to their target mRNA sequences (i.e. microRNA response element, MRE) [
11]. In 2011, Salmena et al. [
12] proposed the competing endogenous RNA (ceRNA) hypothesis, which states that mRNAs, transcribed pseudogenes, and lncRNAs could act as natural miRNA “sponges” and inhibit miRNA function by competing with the binding of one or more MREs in complex and comprehensive regulatory networks, leading to pathogenic conditions. The ceRNA regulation theory has been proven to be involved in bladder cancer initiation and progression in several studies [
13,
14]. Similarly, lncRNAs acting as ceRNAs has also been reported in other cancers [
15‐
17]. Recently, Kouhsar et al. [
18] constructed a ceRNA network related to the staging of Non-Muscle Invasive Bladder Cancer (Ta and T1) derived from public data sources. They identified several biomarkers associated with tumor stage. We hypothesized that lncRNAs may function as ceRNAs during BUC initiation and progression. Understanding how lncRNAs function as ceRNAs will be important in deciphering BUC carcinogenesis.
In the present study, we aimed to decipher the regulatory ceRNA network of lncRNAs–miRNAs–mRNAs in BUC by analyzing gene expression data. This was performed using bioinformatics prediction and correlation analyses. In addition, using clinical trials and survival analyses, we identified potential prognostic genes.
Discussion
In this study, five DElncRNA factors (HCG22, ADAMTS9-AS1, ADAMTS9-AS2, AC078778.1, and AC112721.1) in the ceRNAs network were identified as independent prognostic factors for OS in BUC patients. HCG22 expression levels have been reported to be down-regulated in oral cancer and its low expression was associated with poor survival in a recent study based on TCGA data analysis [
22]. Lu et al. [
23] investigated HCG22 expression levels in 20 oral cavity and oropharyngeal squamous cell carcinoma (OSCC) samples and 10 control samples by qRT-PCR. They demonstrated that HCG22 was downregulated in OSCC tissues compared to controls, while no association was observed between HCG22 expression levels and overall survival. ADAMTS9-AS1 (ADAMTS9 antisense transcript), is a novel lncRNA without any functional annotation but could interact with two RNA-binding proteins, DCGR8 and FUS [
24]. lncRNAs play an important role in cancer mainly via their associations with RNA-binding g proteins, which include HOTTIP, MaLAT1, H19, and HOTAIR. They participate in several biological pathways involved in cell differentiation and proliferation, apoptosis and tumorigenesis by interacting with RNA-binding proteins in hepatocellular carcinoma [
25]. We hypothesized that ADAMTS9-AS1 may play a role in the development of cancer. Wang et al. [
26] found that ADAMTS9-1 and ADAMTS9-2 expression levels were decreased in malignant epithelial ovarian cancer tissues compared to normal ovary tissues and benign ovarian cysts using lncRNA and mRNA microarray analysis. These results were confirmed using 8 normal ovarian, 17 benign ovarian cysts and 15 malignant epithelial ovarian cancer samples by qPCR assays. Low ADAMTS9-AS2 levels were found to be a significant independent predictor of poor survival in glioma patients [
27]. Liu et al. [
28] suggested that lncRNA ADAMTS9-AS2 could suppress cancer progression by inhibiting miR-223-3p and activating TGFBR3. Additionally, increased ADAMTS9-AS2 levels could reduce lung cancer tumor size and improve OS. However, to date, no studies have been performed to determine the role of AC078778.1 and AC112721.1 in cancer.
miRNAs are involved in multiple roles during carcinogenesis. In this study, we found two independent prognostic DEmiRNA factors (hsa-mir-141 and hsa-mir-145) that were involved in the ceRNA network. miR-141 was found to be up-regulated in malignant bladder tissue samples compared to healthy tissues and was a favorable prognostic biomarker [
29]. microRNA-141 (hsa-mir-141) has been shown to exert a regulatory role during epithelial to mesenchymal transition process, and its expression levels have been associated with tumorigenicity and invasiveness in several human cancers. hsa-mir-141 has been shown to be associated with the development of certain epithelial cancer cell types, including prostate [
30], colorectal [
31] and breast cancer [
32]. Huang et al. [
33] demonstrated that miR-141 could inhibit gastric cancer cell proliferation and tumor growth, while low miR-141 levels were associated with poor prognosis. Another study on gastric cancer suggested that miR-141 could play an important anti-tumor role by interacting with MEG3 and targeting E2F3 during gastric cancer pathogenesis and may be a therapeutic target. miR-145 has been frequently observed to be down-regulated in cancers and restoration of miR-145 levels suppressed cancer cell invasion by reversing the EMT phenotype [
34]. Tan et al. [
35] demonstrated that TUG1 promoted bladder cancer cell metastasis and radio-resistance by negatively regulating miR-145 expression.
In the present study, 6 prognostic DEmRNA factors (ZEB1, TMEM100, MAP1B, DUSP2, JUN, and AIFM3) were involved in the ceRNAs network and functioned as independent prognostic factors for OS in BUC patients. Several studies have demonstrated that ZEB1 was significantly overexpressed in bladder cancer tissues compared to normal healthy adjacent tissues [
36]. Li et al. [
37] reported that ZEB1 was significantly overexpressed in bladder cancers compared to normal tissues, and played a crucial role during VM formation, and was closely associated with invasion, metastasis and poor prognosis of malignant tumors [
38,
39]. Transmembrane protein 100 (TMEM100), located at 17q32, was first identified as a transcript in the mouse genome. Han et al. [
32] found that TMEM100 could function as a tumor suppressor by inhibiting the growth and metastasis of non-small-cell lung cancer via the inhibition of the TNF pathway. Low TMEM100 expression levels were associated with poor prognosis. Similar results have been reported for hepatocellular carcinoma [
40]. MAP1B, which encodes for the microtubule-associated protein 1B (MAP1B), is one of the main cytoskeletal proteins. Several studies have demonstrated that MAP1B plays an important role in a number of cellular processes, including synaptic transmission, autophagy, and cancer [
41‐
43]. DUSP2 is a member of the class 1 DUSP family of proteins and is localized in the nucleus. DUSP2 levels are significantly decreased in bladder cancer and low expression of DUSP2 is correlated with poor prognosis [
44]. JUN (C-Jun, AP-1 transcription factor subunit) is specifically phosphorylated by JNK and plays a central role in the AP-1 complex. It is involved in cellular DNA damage response by regulating the expression of several genes [
45,
46]. c-Jun is a proto-oncogene and is involved in transformation and tumor development [
47,
48]. AIFM3 (apoptosis-inducing factor mitochondria associated 3) is a gene with homology to apoptosis-inducing factor (AIF). AIF induces apoptosis in a caspase-dependent manner. AIFM3 was observed to be highly expressed in breast cancer tissues and associated with shorter overall survival and disease-free survival [
49].
BUC specific DEmRNA pathways were assessed using KEGG pathway analysis. Our results demonstrated that the majority of DEmRNAs were frequently enriched for cancer-related pathways. Of these, the neuroactive ligand-receptor interaction signaling pathway has been reported to be associated with the progression of renal cell carcinoma in bioinformatics studies [
50]. In addition, previous studies have suggested that cAMP-related signaling could control apoptosis induction and cell growth [
51,
52], while another study demonstrated that cAMP was an inhibitor of cell cycle progression and apoptosis in gastric cancer cells [
53]. Zhang et al. [
54] showed that the ECM–receptor interaction pathway played a significant role in tumor progression and metastasis. We found several overlapping DEmRNAs that were involved in multiple pathways, such as SLC8A1, CAMK2B, and CACNA2D1, and have been demonstrated to play important roles in cancer pathogenesis. Muñoz reported that lower levels of SLC8A1, which was at least partly mediated by miR-223, was associated with reduced calcium and apoptosis levels in penile carcinoma [
55]. Based on an integrative meta-analysis, CAMK2B was found to be associated with the development of cancer cachexia [
56]. Recently, Feng et al. [
57] assayed 15 colorectal cancer tissues and 10 paracancerous tissues using microarrays and found that CAMK2B was involved in the progression of Fusobacterium nucleatum-induced colorectal cancer. Another study also reported that CAMK2B played an important role in glioblastoma multiforme using bioinformatics analysis on publicly available datasets [
58]. High expression levels of CACNA2D1 in epithelial ovarian cancers were significantly correlated with histological subtypes, advanced FIGO stages and tumor differentiation [
59]. In addition, the majority of PLB4 hotspot mutations are gain-of function mutations that have been demonstrated to be involved in uveal melanoma tumorigenesis by activating the same signaling pathway [
60].
In terms of GO functional enrichment analysis, we found that DEmRNAs were significantly enriched for the regulation of multiple processes, such as binding, protein binding, receptor binding, ion channel activity, and endopeptidase activity. Interestingly, several studies have reported that these functions overlapped in different cancers. Several studies have demonstrated that knocking down ezrin and P65 expression induces tumor metastasis in different cancers [
61,
62]. Furthermore, Tang et al. [
63] demonstrated that ezrin and P65 were physically associated with one another. We hypothesize that the interaction between ezrin and P65 is associated with the activation of the NF-κB pathway leading to breast cancer metastasis. A previous study suggested that Estrogen receptor β could increase the levels of miR-92a by binding to the estrogen-response-element (ERE) leading to a decrease in DAB2IP tumor suppressor expression to ultimately promote bladder cancer growth and invasion [
64]. Numerous studies have demonstrated that ion channels play an important role in tumorigenesis and progression, such as inducing neo-angiogenesis [
65], apoptosis resistance [
66], proliferative potential [
67] as well as cell migration and invasiveness [
68,
69]. In terms of endopeptidase activity, Zhu et al. [
70]. demonstrated that asparaginyl endopeptidase (AEP) was highly expressed in tissues and ascites of patients with epithelial ovarian cancer and promoted tumor growth and progression both in vivo and in vitro.
We then constructed a PPI network to identify hub DEmRNAs. Proteins that corresponded to genes were used to build the PPI network, and the top 30 DEmRNAs with a high degree were selected. KEGG pathway analysis of these 30 DEmRNAs was performed using the “clusterProfiler” package. The results showed that 21 of these 30 DEmRNAs were enriched for “viral carcinogenesis” and “transcriptional dysregulation in cancer”. The 21 identified DEmRNAs may play an important role in cancer. For example, IL6, HIST1H3C, and HIST1H3G, which were classified with high degrees are present in pathways associated with transcriptional dysregulation in cancer. In addition, these three genes have been previously reported to be closely associated with tumorigenesis and development [
71‐
73].
In terms of correlation analysis, a positive correlation between ZEB1 and ADAMTS9-AS1-AS2 and TMEM100 was observed using the Pearson correlation statistic based on the expression levels of these genes. The correlation between these four genes may play an important role in the initiation and progression of BUC. Only a few studies on their interactions have been published in public databases, such as Pubmed and Embase.
Several limitations of the present study should be stated. First, the number of normal bladder tissues (19 samples) was limited and may have compromised the reliability of our results. Second, BUC patient information from TCGA was not validated using experimental procedures. Third, we only investigated the ceRNAs network associated with lncRNAs, miRNAs, and mRNAs, and did not include other regulatory models. Finally, several novel lncRNAs with significant clinical value needs to be investigated to determine their functional role and underlying mechanism during BUC carcinogenesis. We verified the independent prognostic lncRNAs and mRNAs using GEPIA and this supported our findings. Our results provide a better understanding of lncRNA-related ceRNAs and its important role in BUC. Additional experimental and clinical studies are needed to validate our findings.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.